<DOC>
	<DOCNO>NCT01716403</DOCNO>
	<brief_summary>The risk severe anemia increase patient treat tri-therapy compare patient treat bitherapy . The underlying mechanism involve toxicity remain unexplored could also depend global exposure telaprevir . The trough concentration AUC telaprevir could therefore predictive factor onset anemia patient treat ribavirin/PEG-INF/telaprevir . The early measurement telaprevir ribavirin concentration could help manage HCV tri-therapy improve tolerance SVR .</brief_summary>
	<brief_title>Telaprevir Exposure Severe Anemia HCV Infected Patients Treated Tri-therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Man woman older 18 yr. 2 HCV genotype 1 infection confirm positive viral load 6 month selection visit confirm mean liver biopsy within 1 year screening study . 3 Patient one follow criterion : Patient naive treatment HCV infection Or Prior null responder patient : patient previously treat ribavirin/PEGINF least 12 week HCV viral load decline &lt; 2 log week 12 Or Prior partial responder patient : patient previously treat ribavirin/PEGINF least 12 week , never negative viral load viral load decline &gt; 2 log week 12 Or Prior relapser patient : patient previously treat ribavirin/PEGINF 48 week , negative viral load end treatment positive viral load 6 month later 4 Patient stop treatment least 12 week 5 Patient liver biopsy Fibroscan within 24 month start study Metavir fibrosis score F â‰¥ 3 . 6 Patient fulfills criteria telaprevir treatment define licence 7 Patients accepts use 2 contraceptive method 6 month end treatment 8 Patient give write informed consent 10 Patient insured french social security system 1 Infection/coinfection HCV genotype different genotype 1 2 Patient medical contraindication PEGINF ribavirin 3 Patient history allergy intolerance telaprevir 4 Patient use contraindicate drug 5 Patient history decompensated liver disease and/or present biochemical measurement follow inclusion visit : International Normalized Ratio ( INR ) &gt; 1,5 Albumin &lt; 3,3 g/dl Total bilirubin &gt; 1,8 N apart patient Gilbert syndrome 6 Liver disease cause 7 Patient hepatocellular carcinoma history cancer 8 Patient history graft transplantation treat immunosuppressive drug 9 Patient regularly treat corticosteroid 11 Patient hemophilia coagulation trouble 12 HIV HBV coinfection 14 Patient body mass index &gt; 30 kg/m2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>C hepatitis , telaprevir concentration , ribavirin oncentration , anemia</keyword>
</DOC>